Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
- PMID: 22146979
- PMCID: PMC3526101
- DOI: 10.1007/s00432-011-1103-0
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
Abstract
Purpose: The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer.
Methods: We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer.
Results: We found the following: (1) PIK3CA rs6443624 and rs9838411 variants either borderline or significantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39-1.00 and 0.59; 95% CI, 0.36-0.95, respectively). Furthermore, there was a statistically significant multiplicative interaction (P (int) = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1 rs2498801 genotype significantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. (3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003).
Conclusion: These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to confirm these findings.
Figures

Similar articles
-
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.J Clin Oncol. 2009 Feb 20;27(6):857-71. doi: 10.1200/JCO.2008.17.6297. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164214 Free PMC article.
-
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.Oncotarget. 2017 Mar 21;8(12):20252-20265. doi: 10.18632/oncotarget.15690. Oncotarget. 2017. PMID: 28423632 Free PMC article.
-
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.Cancer Discov. 2011 Jul;1(2):170-85. doi: 10.1158/2159-8290.CD-11-0039. Epub 2011 Jun 7. Cancer Discov. 2011. PMID: 21984976 Free PMC article.
-
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Oncotarget. 2012 Sep;3(9):954-87. doi: 10.18632/oncotarget.652. Oncotarget. 2012. PMID: 23006971 Free PMC article. Review.
-
Role of signaling pathways in endometrial cancer.Mol Biol Rep. 2025 Apr 21;52(1):408. doi: 10.1007/s11033-025-10523-1. Mol Biol Rep. 2025. PMID: 40257522 Review.
Cited by
-
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4. Cancer Cell. 2014. PMID: 25002028 Free PMC article. Clinical Trial.
-
Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population.J Cell Mol Med. 2016 Apr;20(4):666-77. doi: 10.1111/jcmm.12750. Epub 2016 Feb 1. J Cell Mol Med. 2016. PMID: 26828791 Free PMC article.
-
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.Int J Clin Exp Pathol. 2015 Oct 1;8(10):13360-6. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26722541 Free PMC article.
-
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.Nat Genet. 2024 Apr;56(4):637-651. doi: 10.1038/s41588-024-01703-z. Epub 2024 Apr 2. Nat Genet. 2024. PMID: 38565644
-
A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population.Sci Rep. 2016 Jan 28;6:20008. doi: 10.1038/srep20008. Sci Rep. 2016. PMID: 26818920 Free PMC article.
References
-
- Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon YCS, Xercavins J, Alameda F, Reventos J (2006) Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 21(2):197–204 - PubMed
-
- Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296–315 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous